Oral administration of Lactobacillus rhamnosus CCFM0528 improves glucose tolerance and cytokine secretion in high-fat-fed, streptozotocin-induced type 2 diabetic mice

In this study, the effects of Lactobacillus rhamnosus CCFM0528, a new probiotic strain isolated by our laboratory, on glucose tolerance, hyperglycemia and cytokine secretion in high-fat-fed, streptozotocin-induced type 2 diabetic mice were studied. The results indicate that L. rhamnosus CCFM0528 significantly decreased fasting and postprandial 2-h blood glucose, glycosylated hemoglobin (HbA1c), endotoxin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) levels compared with the control group (P <0.05). However, the values for insulin, glycogen, interleukin-4 (IL-4), and interleukin-10 (IL-10) were effectively increased at 13 weeks (P <0.05). The cytokine gene expressions in spleen were regulated, and the islet cells were protected by L. rhamnosus CCFM0528. These findings demonstrated the antidiabetic effect of L. rhamnosus CCFM0528 on mice with type 2 diabetic induced by a high-fat diet and streptozotocin. Our study suggested that L. rhamnosus CCFM0528 may be a promising therapeutic agent in treating type 2 diabetes.